OncoMed Announces Year-End Cash Balance and 2017 Outlook

OncoMed Announces Year-End Cash Balance and 2017 Outlook


OncoMed Pharmaceuticals Inc. , a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today pre-announced its 2016 year-end cash balance and reviewed key anticipated events for 2017. OncoMed ended 2016 with approximately $184.6 million in cash.



from Biotech News